Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
P/B ratio for Exact Sciences Corporation (EXAS)
P/B ratio as of 2023: 4.24
According to Exact Sciences Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.24. At the end of 2022 the company had a P/B ratio of 2.87.
P/B ratio history for Exact Sciences Corporation from 1998 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.24 |
| 2022 | 2.87 |
| 2021 | 3.94 |
| 2020 | 7.09 |
| 2019 | 5.31 |
| 2018 | 11.32 |
| 2017 | 11.68 |
| 2016 | 4.08 |
| 2015 | 2.60 |
| 2014 | 7.62 |
| 2013 | 5.86 |
| 2012 | 6.39 |
| 2011 | 5.11 |
| 2010 | 3.03 |
| 2009 | 18.13 |
| 2008 | -6.38 |
| 2007 | 13.80 |
| 2006 | 5.02 |
| 2005 | 2.36 |
| 2004 | 2.55 |
| 2003 | 15.65 |
| 2002 | 5.21 |
| 2001 | 2.87 |
| 2000 | 0.79 |
| 1999 | 3.17 |
| 1998 | 0.95 |